{
    "info": {
        "nct_id": "NCT06092333",
        "official_title": "A Pilot Study of the Combination of VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B",
        "inclusion_criteria": "* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age >=18-65 years\n2. HBsAg positive with a level <2,000 IU/mL at the time of screening\n3. Hepatitis B e antigen negative\n4. HBV DNA levels <10,000 IU/mL on two occasions at least 24 weeks apart with the second being at time of screening\n5. ALT level <=2 ULN (using sex-specific cut-offs of normal 35 U/L for males and 25 U/L for females) based on at least two determinations taken at least 24 weeks apart with the second being at time of screening\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnancy or lactation\n2. For women of childbearing potential, inability, or unwillingness to use highly effective contraception during study drug dosing and for an additional 24 weeks after the end of study drug administration.\n3. For males of reproductive potential: Unable or unwilling to use condoms consistently in addition to female partner using another adequate contraceptive method to ensure effective contraception with partner during study participation and for an additional 24 weeks after the end of study medication administration. Patients who have underwent surgical sterilization (vasectomy) will still require female partner to utilize an additional adequate contraception method.\n4. Known history of hypersensitivity or contraindication to an siRNA, oligonucleotide, or GalNAc or any interferon product\n5. Current use of oral theophylline and methadone\n6. Any treatment for HBV within the last 24 weeks\n7. Prior exposure to a siRNA\n8. Co-infection with HDV as defined by the presence of anti-HDV in serum.\n9. Co-infection with HCV as defined by the presence of anti-HCV and HCV RNA in serum.\n10. Co-infection with HIV as defined by the presence of anti-HIV in serum\n11. Cirrhosis either diagnosed by a prior liver biopsy at any time or, if not available, by a transient elastography score >13 kPa\n12. Decompensated liver disease as defined by serum bilirubin >2.5 mg/dL (with direct bilirubin > 1.5 mg/dL), prothrombin time of greater than 2 seconds prolonged, a serum albumin of less than 3.5 g/dL, or a history of ascites, variceal bleeding or hepatic encephalopathy\n13. Hepatocellular carcinoma (HCC), or the presence of a mass on imaging studies of the liver that is suggestive of HCC, or an alpha-fetoprotein level of greater than 500 ng/mL\n14. Presence of other causes of liver disease, (i.e. hemochromatosis, Wilson disease, alcoholic liver disease, severe steatosis, alpha-1-anti-trypsin deficiency)\n15. A history of solid organ or bone marrow transplant\n16. Any current medical condition requiring the chronic use of more than 10 mg of prednisone (or its equivalent) daily or biologics (e.g. monoclonal antibody, interferon) within 3 months of screening.\n17. Significant systemic illness other than liver diseases including congestive heart failure, renal failure, chronic pancreatitis and diabetes mellitus with poor control (hemoglobin A 1C (HgbA1C >8.5)), that in the opinion of the investigator may interfere with therapy.\n18. eGFR < 60 ml/min, serum creatinine > 1.3 mg/dl\n19. Platelet count <90 mm3/dL\n20. Hgb <12 g/dL for males and <11 g/dL for females\n21. White Blood cell count < 2500 cells/mm3\n22. Neutrophil count < 1500 cell/mm3 (or < 1000 cell/mm3 if considered a physiological variant in a subject of African descent)\n23. Active ethanol/drug abuse/psychiatric problems such as major depression, schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety, or personality disorder that, in the investigator s opinion, might interfere with participation in the study.\n24. History of malignancy or treatment for a malignancy within the past 3 years (except adequately treated carcinoma in situ or basal cell carcinoma of the skin).\n25. History of immune-mediated disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis, sarcoidosis, psoriasis of greater than mild severity, autoimmune uveitis), or cerebrovascular, chronic pulmonary or cardiac disease associated with functional limitation, retinopathy, uncontrolled thyroid disease, (TSH >10 or <0.4mU/L) or uncontrolled seizure disorder, as determined by a study physician.\n26. Use of another investigational agent within 90 days of screening\n27. Use of any prohibited immunosuppressants (except short term use of prednisone as a steroid burst [<= 1 week of use]) or cytotoxic medications\n28. Presence of conditions that, in the opinion of the investigators, would not allow the patient to be followed in the current study.\n29. Inability of subject to understand and the unwillingness to sign a written informed consent document\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "11. Cirrhosis either diagnosed by a prior liver biopsy at any time or, if not available, by a transient elastography score >13 kPa",
            "criterions": [
                {
                    "exact_snippets": "Cirrhosis either diagnosed by a prior liver biopsy at any time",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "prior liver biopsy"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if not available, by a transient elastography score >13 kPa",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "transient elastography"
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">",
                                "value": 13,
                                "unit": "kPa"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. HBV DNA levels <10,000 IU/mL on two occasions at least 24 weeks apart with the second being at time of screening",
            "criterions": [
                {
                    "exact_snippets": "HBV DNA levels <10,000 IU/mL on two occasions at least 24 weeks apart with the second being at time of screening",
                    "criterion": "HBV DNA levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10000,
                                "unit": "IU/mL"
                            }
                        },
                        {
                            "requirement_type": "number of measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "occasions"
                            }
                        },
                        {
                            "requirement_type": "time interval between measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing of second measurement",
                            "expected_value": "at time of screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Prior exposure to a siRNA",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to a siRNA",
                    "criterion": "siRNA exposure",
                    "requirements": [
                        {
                            "requirement_type": "history of exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Hepatocellular carcinoma (HCC), or the presence of a mass on imaging studies of the liver that is suggestive of HCC, or an alpha-fetoprotein level of greater than 500 ng/mL",
            "criterions": [
                {
                    "exact_snippets": "Hepatocellular carcinoma (HCC)",
                    "criterion": "hepatocellular carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of a mass on imaging studies of the liver that is suggestive of HCC",
                    "criterion": "liver mass suggestive of HCC on imaging",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alpha-fetoprotein level of greater than 500 ng/mL",
                    "criterion": "alpha-fetoprotein level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "24. History of malignancy or treatment for a malignancy within the past 3 years (except adequately treated carcinoma in situ or basal cell carcinoma of the skin).",
            "criterions": [
                {
                    "exact_snippets": "History of malignancy ... within the past 3 years",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "treatment for a malignancy within the past 3 years",
                    "criterion": "malignancy treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except adequately treated carcinoma in situ or basal cell carcinoma of the skin",
                    "criterion": "carcinoma in situ or basal cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "adequate_treatment_exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Presence of other causes of liver disease, (i.e. hemochromatosis, Wilson disease, alcoholic liver disease, severe steatosis, alpha-1-anti-trypsin deficiency)",
            "criterions": [
                {
                    "exact_snippets": "Presence of other causes of liver disease, (i.e. hemochromatosis",
                    "criterion": "hemochromatosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of other causes of liver disease, (i.e. ... Wilson disease",
                    "criterion": "Wilson disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of other causes of liver disease, (i.e. ... alcoholic liver disease",
                    "criterion": "alcoholic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of other causes of liver disease, (i.e. ... severe steatosis",
                    "criterion": "severe steatosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of other causes of liver disease, (i.e. ... alpha-1-anti-trypsin deficiency",
                    "criterion": "alpha-1-anti-trypsin deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 65 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 65 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pregnancy or lactation",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactation",
                    "criterion": "lactation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "28. Presence of conditions that, in the opinion of the investigators, would not allow the patient to be followed in the current study.",
            "criterions": [
                {
                    "exact_snippets": "Presence of conditions that, in the opinion of the investigators, would not allow the patient to be followed in the current study.",
                    "criterion": "conditions interfering with study follow-up",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "would not allow the patient to be followed in the current study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "27. Use of any prohibited immunosuppressants (except short term use of prednisone as a steroid burst [<= 1 week of use]) or cytotoxic medications",
            "criterions": [
                {
                    "exact_snippets": "Use of any prohibited immunosuppressants (except short term use of prednisone as a steroid burst [<= 1 week of use])",
                    "criterion": "prohibited immunosuppressant use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "short term use of prednisone as a steroid burst [<= 1 week of use]"
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of any ... cytotoxic medications",
                    "criterion": "cytotoxic medication use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. HBsAg positive with a level <2,000 IU/mL at the time of screening",
            "criterions": [
                {
                    "exact_snippets": "HBsAg positive",
                    "criterion": "HBsAg",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "level <2,000 IU/mL at the time of screening",
                    "criterion": "HBsAg level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2000,
                                "unit": "IU/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. White Blood cell count < 2500 cells/mm3",
            "criterions": [
                {
                    "exact_snippets": "White Blood cell count < 2500 cells/mm3",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2500,
                                "unit": "cells/mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. For males of reproductive potential: Unable or unwilling to use condoms consistently in addition to female partner using another adequate contraceptive method to ensure effective contraception with partner during study participation and for an additional 24 weeks after the end of study medication administration. Patients who have underwent surgical sterilization (vasectomy) will still require female partner to utilize an additional adequate contraception method.",
            "criterions": [
                {
                    "exact_snippets": "males of reproductive potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Unable or unwilling to use condoms consistently in addition to female partner using another adequate contraceptive method ... during study participation and for an additional 24 weeks after the end of study medication administration",
                    "criterion": "contraceptive use (male and female partner)",
                    "requirements": [
                        {
                            "requirement_type": "condom use (male)",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "female partner contraceptive use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of study participation"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 24,
                                        "unit": "weeks after end of study medication"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have underwent surgical sterilization (vasectomy) will still require female partner to utilize an additional adequate contraception method",
                    "criterion": "contraceptive use (female partner of vasectomized male)",
                    "requirements": [
                        {
                            "requirement_type": "male surgical sterilization (vasectomy)",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "female partner contraceptive use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Current use of oral theophylline and methadone",
            "criterions": [
                {
                    "exact_snippets": "Current use of oral theophylline",
                    "criterion": "oral theophylline use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current use of ... methadone",
                    "criterion": "methadone use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Known history of hypersensitivity or contraindication to an siRNA, oligonucleotide, or GalNAc or any interferon product",
            "criterions": [
                {
                    "exact_snippets": "Known history of hypersensitivity ... to an siRNA, oligonucleotide, or GalNAc or any interferon product",
                    "criterion": "hypersensitivity",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent",
                            "expected_value": [
                                "siRNA",
                                "oligonucleotide",
                                "GalNAc",
                                "interferon product"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "contraindication to an siRNA, oligonucleotide, or GalNAc or any interferon product",
                    "criterion": "contraindication",
                    "requirements": [
                        {
                            "requirement_type": "agent",
                            "expected_value": [
                                "siRNA",
                                "oligonucleotide",
                                "GalNAc",
                                "interferon product"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age >=18-65 years",
            "criterions": [
                {
                    "exact_snippets": "Age >=18-65 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 65,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Platelet count <90 mm3/dL",
            "criterions": [
                {
                    "exact_snippets": "Platelet count <90 mm3/dL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 90,
                                "unit": "mm3/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. ALT level <=2 ULN (using sex-specific cut-offs of normal 35 U/L for males and 25 U/L for females) based on at least two determinations taken at least 24 weeks apart with the second being at time of screening",
            "criterions": [
                {
                    "exact_snippets": "ALT level <=2 ULN (using sex-specific cut-offs of normal 35 U/L for males and 25 U/L for females)",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "sex-specific cut-off",
                            "expected_value": [
                                "35 U/L for males",
                                "25 U/L for females"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "based on at least two determinations taken at least 24 weeks apart with the second being at time of screening",
                    "criterion": "ALT level measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "number of determinations",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "determinations"
                            }
                        },
                        {
                            "requirement_type": "interval between determinations",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing of second determination",
                            "expected_value": "at time of screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Hepatitis B e antigen negative",
            "criterions": [
                {
                    "exact_snippets": "Hepatitis B e antigen negative",
                    "criterion": "Hepatitis B e antigen",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Co-infection with HIV as defined by the presence of anti-HIV in serum",
            "criterions": [
                {
                    "exact_snippets": "Co-infection with HIV as defined by the presence of anti-HIV in serum",
                    "criterion": "HIV co-infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of anti-HIV in serum",
                    "criterion": "anti-HIV in serum",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. A history of solid organ or bone marrow transplant",
            "criterions": [
                {
                    "exact_snippets": "A history of solid organ or bone marrow transplant",
                    "criterion": "history of solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "A history of solid organ or bone marrow transplant",
                    "criterion": "history of bone marrow transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Significant systemic illness other than liver diseases including congestive heart failure, renal failure, chronic pancreatitis and diabetes mellitus with poor control (hemoglobin A 1C (HgbA1C >8.5)), that in the opinion of the investigator may interfere with therapy.",
            "criterions": [
                {
                    "exact_snippets": "Significant systemic illness other than liver diseases",
                    "criterion": "systemic illness (excluding liver diseases)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "renal failure",
                    "criterion": "renal failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic pancreatitis",
                    "criterion": "chronic pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diabetes mellitus with poor control (hemoglobin A 1C (HgbA1C >8.5))",
                    "criterion": "diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "poor"
                        },
                        {
                            "requirement_type": "hemoglobin A1C",
                            "expected_value": {
                                "operator": ">",
                                "value": 8.5,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "that in the opinion of the investigator may interfere with therapy",
                    "criterion": "potential to interfere with therapy (per investigator judgment)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "29. Inability of subject to understand and the unwillingness to sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "Inability of subject to understand",
                    "criterion": "subject's ability to understand",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unwillingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. eGFR < 60 ml/min, serum creatinine > 1.3 mg/dl",
            "criterions": [
                {
                    "exact_snippets": "eGFR < 60 ml/min",
                    "criterion": "eGFR",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum creatinine > 1.3 mg/dl",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.3,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Decompensated liver disease as defined by serum bilirubin >2.5 mg/dL (with direct bilirubin > 1.5 mg/dL), prothrombin time of greater than 2 seconds prolonged, a serum albumin of less than 3.5 g/dL, or a history of ascites, variceal bleeding or hepatic encephalopathy",
            "criterions": [
                {
                    "exact_snippets": "serum bilirubin >2.5 mg/dL (with direct bilirubin > 1.5 mg/dL)",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum bilirubin >2.5 mg/dL (with direct bilirubin > 1.5 mg/dL)",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prothrombin time of greater than 2 seconds prolonged",
                    "criterion": "prothrombin time",
                    "requirements": [
                        {
                            "requirement_type": "prolongation",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "seconds"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum albumin of less than 3.5 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... variceal bleeding",
                    "criterion": "variceal bleeding",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... hepatic encephalopathy",
                    "criterion": "hepatic encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Co-infection with HCV as defined by the presence of anti-HCV and HCV RNA in serum.",
            "criterions": [
                {
                    "exact_snippets": "presence of anti-HCV",
                    "criterion": "anti-HCV antibody in serum",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of ... HCV RNA in serum",
                    "criterion": "HCV RNA in serum",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Hgb <12 g/dL for males and <11 g/dL for females",
            "criterions": [
                {
                    "exact_snippets": "Hgb <12 g/dL for males",
                    "criterion": "hemoglobin (Hgb) level in males",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 12,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "<11 g/dL for females",
                    "criterion": "hemoglobin (Hgb) level in females",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 11,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. Active ethanol/drug abuse/psychiatric problems such as major depression, schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety, or personality disorder that, in the investigator s opinion, might interfere with participation in the study.",
            "criterions": [
                {
                    "exact_snippets": "Active ethanol/drug abuse",
                    "criterion": "ethanol or drug abuse",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric problems such as major depression, schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety, or personality disorder",
                    "criterion": "psychiatric problems",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "major depression",
                                "schizophrenia",
                                "bipolar illness",
                                "obsessive-compulsive disorder",
                                "severe anxiety",
                                "personality disorder"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "that, in the investigator s opinion, might interfere with participation in the study",
                    "criterion": "potential to interfere with study participation (per investigator's opinion)",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with participation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment by",
                            "expected_value": "investigator's opinion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "26. Use of another investigational agent within 90 days of screening",
            "criterions": [
                {
                    "exact_snippets": "Use of another investigational agent within 90 days of screening",
                    "criterion": "use of another investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": "<",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing reference",
                            "expected_value": "of screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Any current medical condition requiring the chronic use of more than 10 mg of prednisone (or its equivalent) daily or biologics (e.g. monoclonal antibody, interferon) within 3 months of screening.",
            "criterions": [
                {
                    "exact_snippets": "Any current medical condition requiring the chronic use of more than 10 mg of prednisone (or its equivalent) daily",
                    "criterion": "chronic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone equivalent"
                            }
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "daily"
                        }
                    ]
                },
                {
                    "exact_snippets": "Any current medical condition requiring the chronic use of ... biologics (e.g. monoclonal antibody, interferon) within 3 months of screening.",
                    "criterion": "chronic biologic use",
                    "requirements": [
                        {
                            "requirement_type": "drug_class",
                            "expected_value": [
                                "monoclonal antibody",
                                "interferon"
                            ]
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months before screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Any treatment for HBV within the last 24 weeks",
            "criterions": [
                {
                    "exact_snippets": "Any treatment for HBV within the last 24 weeks",
                    "criterion": "treatment for HBV",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "22. Neutrophil count < 1500 cell/mm3 (or < 1000 cell/mm3 if considered a physiological variant in a subject of African descent)",
            "criterions": [
                {
                    "exact_snippets": "Neutrophil count < 1500 cell/mm3 (or < 1000 cell/mm3 if considered a physiological variant in a subject of African descent)",
                    "criterion": "neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 1500,
                                        "unit": "cell/mm3"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (African descent, physiological variant)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 1000,
                                        "unit": "cell/mm3"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "25. History of immune-mediated disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis, sarcoidosis, psoriasis of greater than mild severity, autoimmune uveitis), or cerebrovascular, chronic pulmonary or cardiac disease associated with functional limitation, retinopathy, uncontrolled thyroid disease, (TSH >10 or <0.4mU/L) or uncontrolled seizure disorder, as determined by a study physician.",
            "criterions": [
                {
                    "exact_snippets": "History of immune-mediated disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis, sarcoidosis, psoriasis of greater than mild severity, autoimmune uveitis)",
                    "criterion": "immune-mediated disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psoriasis of greater than mild severity",
                    "criterion": "psoriasis severity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "mild"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular ... disease associated with functional limitation",
                    "criterion": "cerebrovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "functional limitation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic pulmonary ... disease associated with functional limitation",
                    "criterion": "chronic pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "functional limitation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac disease associated with functional limitation",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "functional limitation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "retinopathy",
                    "criterion": "retinopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled thyroid disease, (TSH >10 or <0.4mU/L)",
                    "criterion": "thyroid disease",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "TSH >10 or <0.4mU/L",
                    "criterion": "TSH level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 10,
                                        "unit": "mU/L"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 0.4,
                                        "unit": "mU/L"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled seizure disorder",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Co-infection with HDV as defined by the presence of anti-HDV in serum.",
            "criterions": [
                {
                    "exact_snippets": "Co-infection with HDV as defined by the presence of anti-HDV in serum",
                    "criterion": "HDV co-infection",
                    "requirements": [
                        {
                            "requirement_type": "presence of anti-HDV in serum",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. For women of childbearing potential, inability, or unwillingness to use highly effective contraception during study drug dosing and for an additional 24 weeks after the end of study drug administration.",
            "criterions": [
                {
                    "exact_snippets": "women of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "inability, or unwillingness to use highly effective contraception during study drug dosing and for an additional 24 weeks after the end of study drug administration",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "ability to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception type",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "contraception duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of study drug dosing"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 24,
                                        "unit": "weeks after end of study drug administration"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "In order to be eligible to participate in this study, an individual must meet all of the following criteria:",
            "criterions": []
        },
        {
            "line": "* INCLUSION CRITERIA:",
            "criterions": []
        },
        {
            "line": "EXCLUSION CRITERIA:",
            "criterions": []
        },
        {
            "line": "An individual who meets any of the following criteria will be excluded from participation in this study:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}